Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

The future of hybrid ablation: an emerging need for an anticoagulation protocol for thoracoscopic ablation

P. Osmancik, P. Budera

. 2017 ; 9 (3) : E322-E326. [pub] -

Language English Country China

Document type Editorial, Comment, Research Support, Non-U.S. Gov't

Grant support
NV16-32478A MZ0 CEP Register

The midterm efficacy of hybrid ablation of atrial fibrillation (AF) reported in recent papers is about 70% in terms of sinus rhythm maintenance without antiarrhythmic drugs. Bearing in mind that the majority of patients enrolled are patients with persistent and long-standing persistent AF, the reported efficacies seem to be very good. Despite the high efficacies, safety remains a critical issue in hybrid, and especially thoracoscopic ablations. The frequency of complications during thoracoscopic ablations is more than 10% in the majority of reports. Most are short-term with no sequelae (such as pneumothorax or pneumonia); however, life-threatening complications have also been described, e.g., a sternotomy in response to a laceration of the left atrium (LA). One of the most serious ablation complications is stroke. The rate of strokes, which has been reported during or shortly after thoracoscopic ablation, seems to be higher than the rate reported after catheter ablation. This is especially true in papers describing thoracoscopic ablations that were not immediately followed by a catheter ablation. A possible explanation is differences in anticoagulation management during the two procedures. During catheter endocardial procedures, a standard anticoagulation protocol exists and is routinely applied; however, there is no such set of recommendations for anticoagulation during the thoracoscopic-phase of an ablation. It seems probable that, in many cases, no anticoagulation is used during thoracoscopic ablations. Moreover, whatever anticoagulation protocol is used during thoracoscopic ablations often goes unreported. A discussion about the best anticoagulation strategy during thoracoscopic ablation is urgently needed. In the future, standards of anticoagulation during thoracoscopic ablation should be clearly reported, just as they are now for catheter ablations.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22007005
003      
CZ-PrNML
005      
20230112092511.0
007      
ta
008      
220223s2017 cc f 000 0|eng||
009      
AR
024    7_
$a 10.21037/jtd.2017.02.95 $2 doi
035    __
$a (PubMed)28449532
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a cc
100    1_
$a Osmančík, Pavel, $u Cardiocenter, Third Faculty of Medicine, Charles University Prague and University Hospital Kralovske Vinohrady, Prague, Czech Republic $d 1972- $7 xx0104796
245    14
$a The future of hybrid ablation: an emerging need for an anticoagulation protocol for thoracoscopic ablation / $c P. Osmancik, P. Budera
520    9_
$a The midterm efficacy of hybrid ablation of atrial fibrillation (AF) reported in recent papers is about 70% in terms of sinus rhythm maintenance without antiarrhythmic drugs. Bearing in mind that the majority of patients enrolled are patients with persistent and long-standing persistent AF, the reported efficacies seem to be very good. Despite the high efficacies, safety remains a critical issue in hybrid, and especially thoracoscopic ablations. The frequency of complications during thoracoscopic ablations is more than 10% in the majority of reports. Most are short-term with no sequelae (such as pneumothorax or pneumonia); however, life-threatening complications have also been described, e.g., a sternotomy in response to a laceration of the left atrium (LA). One of the most serious ablation complications is stroke. The rate of strokes, which has been reported during or shortly after thoracoscopic ablation, seems to be higher than the rate reported after catheter ablation. This is especially true in papers describing thoracoscopic ablations that were not immediately followed by a catheter ablation. A possible explanation is differences in anticoagulation management during the two procedures. During catheter endocardial procedures, a standard anticoagulation protocol exists and is routinely applied; however, there is no such set of recommendations for anticoagulation during the thoracoscopic-phase of an ablation. It seems probable that, in many cases, no anticoagulation is used during thoracoscopic ablations. Moreover, whatever anticoagulation protocol is used during thoracoscopic ablations often goes unreported. A discussion about the best anticoagulation strategy during thoracoscopic ablation is urgently needed. In the future, standards of anticoagulation during thoracoscopic ablation should be clearly reported, just as they are now for catheter ablations.
650    _7
$a fibrilace síní $x chirurgie $7 D001281 $2 czmesh
650    17
$a ablace $x metody $7 D055011 $2 czmesh
650    _7
$a torakoskopie $x metody $7 D013906 $2 czmesh
650    _7
$a pooperační komplikace $x prevence a kontrola $7 D011183 $2 czmesh
650    _7
$a rizikové faktory kardiovaskulárních chorob $7 D000082742 $2 czmesh
650    _7
$a cévní mozková příhoda $x prevence a kontrola $7 D020521 $2 czmesh
650    _7
$a chemoprofylaxe $x metody $7 D018890 $2 czmesh
650    17
$a antikoagulancia $x terapeutické užití $7 D000925 $2 czmesh
650    _7
$a výsledek terapie $7 D016896 $2 czmesh
650    _7
$a klinické protokoly $7 D002985 $2 czmesh
650    _7
$a lidé $7 D006801 $2 czmesh
655    _2
$a úvodníky $7 D016421
655    _2
$a komentáře $7 D016420
655    _7
$a práce podpořená grantem $7 D013485 $2 czmesh
700    1_
$a Budera, Petr $u Clinic of Cardiac Surgery, University Hospital Kralovske Vinohrady, Charles University, Prague, Czech Republic $7 xx0270813
773    0_
$w MED00194907 $t Journal of thoracic disease $x 2072-1439 $g Roč. 9, č. 3 (2017), s. E322-E326
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28449532 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220223 $b ABA008
991    __
$a 20230112092504 $b ABA008
999    __
$a kom $b bmc $g 1763185 $s 1158185
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 9 $c 3 $d E322-E326 $e - $i 2072-1439 $m Journal of thoracic disease $n J Thorac Dis $x MED00194907
GRA    __
$a NV16-32478A $p MZ0
LZP    __
$c NLK120 $d 20230111 $a 2021-granty

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...